|Author||Al-Thani, Asma A.
|Author||Hamdi, Wedad S.
|Author||Al-Ansari, Naser A.
|Author||Doiphode, Sanjay H.
|Publication Name||BMC infectious diseases||
|Citation||Al-Thani, A.,Hamdi, W., Al-Ansari, N., Doiphode, S.(2014).Polymerase chain reaction ribotyping of Clostridium difficile isolates in Qatar: a hospital-based study.BMC infectious diseases, 14(1):502
Clostridium difficile infection (CDI) is not generally reported to public health authorities in
the Middle East and its true prevalence remains largely unknown. The aims of this study were
to determine the prevalence of CDI and its associated ribotypes among C. difficile isolates in
Qatar. Influence of age and correlation with other risk factors e.g. proton pump inhibitor use,
antibiotic use, existence of chronic conditions, etc was also investigated for CDI positive
A total of 1,532 patients with suspected CDI were recruited from two hospitals between 2011
and 2012. C. difficile was identified using glutamate dehydrogenase (GDH) lateral flow assay
and toxins A and B Enzyme Immunoassay (EIA). The C. difficile positive samples were then
cultured for PCR-ribotyping.
122 of the 1,532 (7.9%) samples from individual patients were identified as C.difficile
positive; and 79 of these were viably cultured (~65%). From these, 36 different PCR
ribotypes were isolated, of which strains 258 (6 [7.6%]), 01/014/046 (5 [6.3%]), and
011/053/056/107 (4 [5%]) were the most prevalent. The prevalence of PCR-ribotype 027 was
1.3% (n = 1). An age of ≥65 years and treatment with proton pump inhibitors correlated with
higher frequency of CDI. Treatment with third generation cephalosporins (50 [41%]) and
piperacillin/tazobactam antibiotics (55 [45.1%]) was most frequently associated with CDI.
The most common C. difficile ribotype identified in Qatar was 258, which is different from
those found in North America, Europe and Asia. The prevalence of CDI was higher in Qatar
than Europe; though comparable to other Middle Eastern countries. These findings
underscore the importance of local surveillance to detect and control C. difficile infection.
|Publisher||BioMed Central Ltd.
|Title||Polymerase chain reaction ribotyping of Clostridium difficile isolates in Qatar: a hospital-based study